TY - JOUR
T1 - In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis
AU - Rupasinghe, Praharshinie
AU - Mulders, Wim
AU - de Jong, Bouke
AU - Rigouts, Leen
AU - Vereecken, Jens
AU - Cirillo, Daniela Maria
AU - Koeser, Claudio U.
AU - Miotto, Paolo
AU - Omar, Shaheed V.
AU - Borroni, Emanuele
AU - Warren, Robin M.
AU - Schön, T
N1 - FTX: (CC BY)
PY - 2025/9/22
Y1 - 2025/9/22
N2 - In vitro experiments with Mycobacterium tuberculosis showed that clofazimine exposure selected for delamanid and pretomanid resistance and mutations in fbiA, fbiC, or fbiD—after the acquisition of Rv0678 mutations where this could be determined. Whether this is also possible in vivo and in an Rv0678 wild-type background has to be studied further. Based on the available evidence, however, we propose that nitroimidazole resistance should not be considered an exclusion criterion for the use of clofazimine.
AB - In vitro experiments with Mycobacterium tuberculosis showed that clofazimine exposure selected for delamanid and pretomanid resistance and mutations in fbiA, fbiC, or fbiD—after the acquisition of Rv0678 mutations where this could be determined. Whether this is also possible in vivo and in an Rv0678 wild-type background has to be studied further. Based on the available evidence, however, we propose that nitroimidazole resistance should not be considered an exclusion criterion for the use of clofazimine.
UR - https://www.webofscience.com/wos/woscc/full-record/WOS:001575510000001
U2 - 10.1128/aac.01113-25
DO - 10.1128/aac.01113-25
M3 - A1: Web of Science-article
SN - 0066-4804
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
ER -